HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Exploring the role of tanezumab as a novel treatment for the relief of neuropathic pain.

AbstractOBJECTIVE:
Evaluate efficacy and safety of tanezumab, a humanized monoclonal antibody against nerve growth factor, in neuropathic pain.
DESIGN:
Two randomized controlled trials.
SUBJECTS:
Patients with pain due to diabetic peripheral neuropathy (DPN) or postherpetic neuralgia (PHN).
METHODS:
In the DPN study, patients received subcutaneous tanezumab 20 mg or placebo on Day 1 and Week 8. Evaluations included change from baseline in average DPN pain (primary endpoint), Patient's Global Assessment of DPN, and safety (including neuropathy assessments). Due to a partial clinical hold limiting enrollment and treatment duration, the prespecified landmark analysis was modified post hoc from Week 16 to Week 8. In the PHN study, patients received intravenous tanezumab 50 μg/kg, tanezumab 200 μg/kg, or placebo on Day 1. Evaluations included change from baseline in average daily pain (primary endpoint), Brief Pain Inventory-short form, Patient's Global Assessment of pain from PHN, and safety.
RESULTS:
Mean DPN pain reduction from baseline to Week 8 was greater with tanezumab vs placebo (P = 0.009); differences in Patient's Global Assessment of DPN were not significant (P > 0.05). Neither tanezumab dose resulted in significant differences vs placebo in efficacy in PHN (P > 0.05), although tanezumab 200 μg/kg provided some benefit. Neuropathy assessments showed no meaningful changes.
CONCLUSIONS:
Tanezumab provided effective pain reduction in DPN. In PHN, only the highest tanezumab dose reduced pain; treatment differences were not significant. No new safety concerns were observed despite preexisting neuropathy.
AuthorsCandace Bramson, David N Herrmann, William Carey, David Keller, Mark T Brown, Christine R West, Kenneth M Verburg, Peter J Dyck
JournalPain medicine (Malden, Mass.) (Pain Med) Vol. 16 Issue 6 Pg. 1163-76 (06 2015) ISSN: 1526-4637 [Electronic] England
PMID25594611 (Publication Type: Clinical Trial, Phase II, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
CopyrightWiley Periodicals, Inc.
Chemical References
  • Antibodies, Monoclonal, Humanized
  • tanezumab
Topics
  • Antibodies, Monoclonal, Humanized (adverse effects, pharmacology, therapeutic use)
  • Dizziness (chemically induced)
  • Double-Blind Method
  • Headache (chemically induced)
  • Humans
  • Neuralgia (diagnosis, drug therapy, epidemiology)
  • Pain Measurement (drug effects, methods)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: